AustralieFrV1, Main, Exploration, bibRecord, 001C73

Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy

Identifieur interne : 001C73 ( Main/Exploration ); précédent : 001C72; suivant : 001C74

Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy

Auteurs : Claire Roger [France, Australie] ; Steven C. Wallis [Australie] ; Laurent Muller [France] ; Gilbert Saissi [France] ; Jeffrey Lipman [Australie] ; Jean-Yves Lefrant [France] ; Jason A. Roberts [Australie]

Source :

Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 2016.

RBID : PMC:4958154

Descripteurs français

KwdFr :
- Amikacine (pharmacocinétique), Amikacine (usage thérapeutique), Antibactériens (pharmacocinétique), Antibactériens (usage thérapeutique), Clairance métabolique (), Femelle, Humains, Hémodiafiltration (), Hémofiltration (), Maladie grave, Mâle, Méthode de Monte-Carlo, Rein (métabolisme), Sujet âgé, Traitement substitutif de l'insuffisance rénale ().
MESH :
- métabolisme : Rein.
- pharmacocinétique : Amikacine, Antibactériens.
- usage thérapeutique : Amikacine, Antibactériens.
- Clairance métabolique, Femelle, Humains, Hémodiafiltration, Hémofiltration, Maladie grave, Mâle, Méthode de Monte-Carlo, Sujet âgé, Traitement substitutif de l'insuffisance rénale.

English descriptors

KwdEn :
- Aged, Amikacin (pharmacokinetics), Amikacin (therapeutic use), Anti-Bacterial Agents (pharmacokinetics), Anti-Bacterial Agents (therapeutic use), Critical Illness, Female, Hemodiafiltration (methods), Hemofiltration (methods), Humans, Kidney (metabolism), Male, Metabolic Clearance Rate (drug effects), Monte Carlo Method, Renal Replacement Therapy (methods).
MESH :
- chemical , pharmacokinetics : Amikacin, Anti-Bacterial Agents.
- chemical , therapeutic use : Amikacin, Anti-Bacterial Agents.
- drug effects : Metabolic Clearance Rate.
- metabolism : Kidney.
- methods : Hemodiafiltration, Hemofiltration, Renal Replacement Therapy.
- Aged, Critical Illness, Female, Humans, Male, Monte Carlo Method.

Abstract

The objective of this study was to describe amikacin pharmacokinetics (PK) in critically ill patients receiving equal doses (30 ml/kg of body weight/h) of continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF). Patients receiving amikacin and undergoing CVVH or CVVHDF were eligible. Population pharmacokinetic analysis and Monte Carlo simulation were undertaken using the Pmetrics software package for R. Sixteen patients (9 undergoing CVVH, 11 undergoing CVVHDF) and 20 sampling intervals were analyzed. A two-compartment linear model best described the data. Patient weight was the only covariate that was associated with drug clearance. The mean ± standard deviation parameter estimates were 25.2 ± 17.3 liters for the central volume, 0.89 ± 1.17 h⁻¹ for the rate constant for the drug distribution from the central to the peripheral compartment, 2.38 ± 6.60 h⁻¹ for the rate constant for the drug distribution from the peripheral to the central compartment, 4.45 ± 2.35 liters/h for hemodiafiltration clearance, and 4.69 ± 2.42 liters/h for hemofiltration clearance. Dosing simulations for amikacin supported the use of high dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h) for most patients when considering PK/pharmacodynamic (PD) targets of a maximum concentration in plasma (C_max)/MIC ratio of ≥8 and a minimal concentration of ≤2.5 mg/liter at the end of the dosing interval. The mean clearance of amikacin was 1.8 ± 1.3 liters/h by CVVHDF and 1.3 ± 1 liters/h by CVVH. On the basis of simulations, a strategy of an extended-interval high loading dose of amikacin (25 mg/kg every 48 h) associated with therapeutic drug monitoring (TDM) should be the preferred approach for aminoglycoside treatment in critically ill patients receiving continuous renal replacement therapy (CRRT). (This study is a substudy of a trial registered at ClinicalTrials.gov under number NCT01403220.)

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958154

DOI: 10.1128/AAC.00828-16
PubMed: 27270279
PubMed Central: 4958154

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy</title>
<author><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C." last="Wallis">Steven C. Wallis</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Saissi, Gilbert" sort="Saissi, Gilbert" uniqKey="Saissi G" first="Gilbert" last="Saissi">Gilbert Saissi</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Pharmacy, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Pharmacy, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff5">Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27270279</idno>
<idno type="pmc">4958154</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958154</idno>
<idno type="RBID">PMC:4958154</idno>
<idno type="doi">10.1128/AAC.00828-16</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000433</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000433</idno>
<idno type="wicri:Area/Pmc/Curation">000433</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000433</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000839</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000839</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001B88</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B88</idno>
<idno type="wicri:Area/PubMed/Curation">001B64</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B64</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001B64</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B64</idno>
<idno type="wicri:Area/Ncbi/Merge">003660</idno>
<idno type="wicri:Area/Ncbi/Curation">003660</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003660</idno>
<idno type="wicri:doubleKey">0066-4804:2016:Roger C:influence:of:renal</idno>
<idno type="wicri:Area/Main/Merge">001C70</idno>
<idno type="wicri:Area/Main/Curation">001C73</idno>
<idno type="wicri:Area/Main/Exploration">001C73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy</title>
<author><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C." last="Wallis">Steven C. Wallis</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Saissi, Gilbert" sort="Saissi, Gilbert" uniqKey="Saissi G" first="Gilbert" last="Saissi">Gilbert Saissi</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Pharmacy, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Nîmes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Pharmacy, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff5">Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Amikacin (pharmacokinetics)</term>
<term>Amikacin (therapeutic use)</term>
<term>Anti-Bacterial Agents (pharmacokinetics)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Critical Illness</term>
<term>Female</term>
<term>Hemodiafiltration (methods)</term>
<term>Hemofiltration (methods)</term>
<term>Humans</term>
<term>Kidney (metabolism)</term>
<term>Male</term>
<term>Metabolic Clearance Rate (drug effects)</term>
<term>Monte Carlo Method</term>
<term>Renal Replacement Therapy (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amikacine (pharmacocinétique)</term>
<term>Amikacine (usage thérapeutique)</term>
<term>Antibactériens (pharmacocinétique)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Clairance métabolique ()</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémodiafiltration ()</term>
<term>Hémofiltration ()</term>
<term>Maladie grave</term>
<term>Mâle</term>
<term>Méthode de Monte-Carlo</term>
<term>Rein (métabolisme)</term>
<term>Sujet âgé</term>
<term>Traitement substitutif de l'insuffisance rénale ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Amikacin</term>
<term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amikacin</term>
<term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Metabolic Clearance Rate</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Kidney</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Hemodiafiltration</term>
<term>Hemofiltration</term>
<term>Renal Replacement Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Rein</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Amikacine</term>
<term>Antibactériens</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amikacine</term>
<term>Antibactériens</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Critical Illness</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Monte Carlo Method</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Clairance métabolique</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémodiafiltration</term>
<term>Hémofiltration</term>
<term>Maladie grave</term>
<term>Mâle</term>
<term>Méthode de Monte-Carlo</term>
<term>Sujet âgé</term>
<term>Traitement substitutif de l'insuffisance rénale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The objective of this study was to describe amikacin pharmacokinetics (PK) in critically ill patients receiving equal doses (30 ml/kg of body weight/h) of continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF). Patients receiving amikacin and undergoing CVVH or CVVHDF were eligible. Population pharmacokinetic analysis and Monte Carlo simulation were undertaken using the Pmetrics software package for R. Sixteen patients (9 undergoing CVVH, 11 undergoing CVVHDF) and 20 sampling intervals were analyzed. A two-compartment linear model best described the data. Patient weight was the only covariate that was associated with drug clearance. The mean ± standard deviation parameter estimates were 25.2 ± 17.3 liters for the central volume, 0.89 ± 1.17 h<sup>−1</sup>
 for the rate constant for the drug distribution from the central to the peripheral compartment, 2.38 ± 6.60 h<sup>−1</sup>
 for the rate constant for the drug distribution from the peripheral to the central compartment, 4.45 ± 2.35 liters/h for hemodiafiltration clearance, and 4.69 ± 2.42 liters/h for hemofiltration clearance. Dosing simulations for amikacin supported the use of high dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h) for most patients when considering PK/pharmacodynamic (PD) targets of a maximum concentration in plasma (<italic>C</italic>
<sub>max</sub>
)/MIC ratio of ≥8 and a minimal concentration of ≤2.5 mg/liter at the end of the dosing interval. The mean clearance of amikacin was 1.8 ± 1.3 liters/h by CVVHDF and 1.3 ± 1 liters/h by CVVH. On the basis of simulations, a strategy of an extended-interval high loading dose of amikacin (25 mg/kg every 48 h) associated with therapeutic drug monitoring (TDM) should be the preferred approach for aminoglycoside treatment in critically ill patients receiving continuous renal replacement therapy (CRRT). (This study is a substudy of a trial registered at ClinicalTrials.gov under number NCT01403220.)</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
<region><li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Nîmes</li>
</settlement>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
</region>
<name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name>
<name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name>
<name sortKey="Saissi, Gilbert" sort="Saissi, Gilbert" uniqKey="Saissi G" first="Gilbert" last="Saissi">Gilbert Saissi</name>
</country>
<country name="Australie"><noRegion><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
</noRegion>
<name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name>
<name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name>
<name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name>
<name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name>
<name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C." last="Wallis">Steven C. Wallis</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C73 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C73 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4958154
   |texte=   Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27270279" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy

Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.